Talis Biomedical Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TLIS research report →
Companytalisbio.com
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19.
- CEO
- Rebecca Markovich
- IPO
- 2021
- Employees
- 99
- HQ
- Menlo Park, CA, US
Price Chart
Valuation
- Market Cap
- $5.18M
- P/E
- -0.08
- P/S
- 12.57
- P/B
- 0.07
- EV/EBITDA
- 0.79
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 90.05%
- Op Margin
- -16217.23%
- Net Margin
- -15050.24%
- ROE
- -63.32%
- ROIC
- -72.27%
Growth & Income
- Revenue
- $412.00K · -88.72%
- Net Income
- $-62,007,000 · 45.13%
- EPS
- $-34.12 · 46.39%
- Op Income
- $-66,815,000
- FCF YoY
- 47.20%
Performance & Tape
- 52W High
- $2.84
- 52W Low
- $1.04
- 50D MA
- $2.37
- 200D MA
- $1.72
- Beta
- 1.32
- Avg Volume
- 1.18K
Get TickerSpark's AI analysis on TLIS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 6, 24 | Leonard Braden Michael | buy | 25,000 |
| Sep 5, 24 | Leonard Braden Michael | buy | 5,100 |
| Sep 3, 24 | Leonard Braden Michael | buy | 500 |
| Aug 30, 24 | Leonard Braden Michael | buy | 151 |
| Aug 28, 24 | Leonard Braden Michael | buy | 1,215 |
| Aug 26, 24 | Leonard Braden Michael | buy | 13,167 |
| Aug 14, 24 | Leonard Braden Michael | other | 0 |
| Jul 31, 24 | Ferrari Patricia | other | 0 |
| Jul 31, 24 | Young John T. Jr. | other | 0 |
| Aug 1, 23 | Lukowiak Andrew A | other | 30,575 |
Our TLIS Coverage
We haven't published any research on TLIS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TLIS Report →